---
title: "11:21 ET\n\t\t\t\n\t\t\t\n\t\t\t\tINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics"
description: "Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors of Aquestive Therapeutics, Inc. after the company's stock plummeted approximately 40% following FDA's identification of de"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272900169.md"
published_at: "2026-01-17T16:22:07.000Z"
---

# 11:21 ET
			
			
				INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

> Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors of Aquestive Therapeutics, Inc. after the company's stock plummeted approximately 40% following FDA's identification of deficiencies in its New Drug Application for Anaphylm. Investors who suffered significant losses are encouraged to contact the firm to discuss their legal options. The FDA's concerns about the application's approvability could impact the upcoming PDUFA action date of January 31, 2026.

**Faruqi & Faruqi, LLP Securities Litigation Partner** **James (Josh) Wilson** **Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options**

**If you suffered significant losses in Aquestive Therapeutics stock or options** and would like to discuss your legal rights, call Faruqi & Faruqi partner **Josh Wilson directly** at **877-247-4292** or **212-983-9330** **(Ext. 1310)**.

**\[You may also click here for additional information\]**

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Continue Reading  

Shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) plunged approximately 40% intraday on Friday after the company disclosed that the U.S. Food and Drug Administration (FDA) identified deficiencies in its New Drug Application (NDA) for Anaphylm, its experimental sublingual film for the treatment of severe allergic reactions, including anaphylaxis. The FDA advised that the unidentified deficiencies currently prevent discussions of labeling and post-marketing requirements, raising concerns about the application's approvability ahead of the January 31, 2026, PDUFA action date.

To learn more about the **Aquestive Therapeutics** investigation, go to **www.faruqilaw.com/AQST** or **call** Faruqi & Faruqi partner **Josh Wilson directly** at **877-247-4292** or **212-983-9330** **(Ext. 1310)**.

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

### Related Stocks

- [AQST.US - Aquestive Therapeutic](https://longbridge.com/en/quote/AQST.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 投資者通知：Faruqi & Faruqi, LLP 正在代表 Aquestive Therapeutics 的投資者調查索賠 | Faruqi & Faruqi, LLP 正在代表 Aquestive Therapeutics, Inc. 的投資者調查潛在的索賠，原因是該公司股價在 FDA 發現其新藥申請 Anaphylm 存在缺陷後大幅下跌。遭受損失的投資者被鼓勵聯 | [Link](https://longbridge.com/en/news/275920901.md) |
| 投資者通知：Faruqi & Faruqi, LLP 正在代表 Aquestive Therapeutics 的投資者進行索賠調查 | Faruqi & Faruqi, LLP 正在代表 Aquestive Therapeutics, Inc. 的投資者調查潛在的索賠，因為該公司的股票因其針對 Anaphylm 的新藥申請存在 FDA 缺陷而下跌了約 40%。遭受重大損失的 | [Link](https://longbridge.com/en/news/275206773.md) |
| 揭示潛力：Karyopharm Therapeutics 的業績預覽 | Karyopharm Therapeutics（納斯達克股票代碼：KPTI）定於 2026 年 2 月 12 日發佈季度財報，分析師預測每股收益（EPS）為-2.10 美元。該公司此前未能達到每股收益預期，導致股價下跌 6.92%。目前，股 | [Link](https://longbridge.com/en/news/275648580.md) |
| Celldex Therapeutics 參加多個國際投資者會議 | Celldex Therapeutics Inc. 將參加多個國際投資者會議，包括 2026 年 2 月 11 日的 Guggenheim 新興前景：生物技術峯會、2026 年 3 月 4 日的 TD Cowen 第 46 屆年度醫療保健會 | [Link](https://longbridge.com/en/news/275320849.md) |
| Aquestive Therapeutics, Inc. 報告 FDA 關於 Anaphylm 新藥申請的通知 | Aquestive Therapeutics, Inc. 於 2026 年 1 月 9 日報告了其 Anaphylm 新藥申請中被 FDA 識別的缺陷。FDA 的審查仍在進行中，尚未做出最終決定，這可能會延遲批准。由於這些缺陷，目前無法進行 | [Link](https://longbridge.com/en/news/272074832.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.